• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca Boosted by Licensing Deals

    AstraZeneca Boosted by Licensing Deals

  2. AstraZeneca Sells Rights of Cancer Drug Caprelsa for $300 Million

    AstraZeneca Sells Rights of Cancer Drug Caprelsa for $300 Million

  3. AstraZeneca plc 2Q 2015 -- Forecast

    AstraZeneca plc 2Q 2015 -- Forecast

  4. Synairgen: AstraZeneca Commences AZD9412 Phase II Asthma Trial

    Synairgen: AstraZeneca Commences AZD9412 Phase II Asthma Trial

  5. Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca

    Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca

  6. FDA Approves AstraZeneca's Lung Cancer Drug Iressa

    FDA Approves AstraZeneca's Lung Cancer Drug Iressa

  7. AstraZeneca Provides Update On Selumetinib In Uveal Melanoma

    AstraZeneca Provides Update On Selumetinib In Uveal Melanoma

  8. Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy

    Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy

  9. LONDON MARKETS: London Stocks On Pace For Third Straight Win As RBS, Rolls-Royce Push Higher

    LONDON MARKETS: London Stocks On Pace For Third Straight Win As RBS, Rolls-Royce Push Higher

  10. London stocks on pace for third straight win as RBS, Rolls-Royce push higher

    London stocks on pace for third straight win as RBS, Rolls-Royce push higher

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.